Cargando…

Expanded neuromuscular morbidity in Hodgkin lymphoma after radiotherapy

Our study aims to quantitate neuromuscular morbidity from radiotherapy in Hodgkin lymphoma including: (i) frequency and (ii) time of onsets for neurological localizations; (iii) degree of disabilities and (iv) number of clinical visits compared to cardiopulmonary Hodgkin lymphoma-radiation complicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Oishi, Tatsuya, Kogelschatz, Cory J, Young, Nathan P, Hoffmann, Ernest M, Staff, Nathan P, Visscher, Sue L, Borah, Bijan J, Krauss, William E, Arumaithurai, Kogulavadanan, Shelly, Shahar, Ansell, Stephen M, Klein, Christopher J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425393/
https://www.ncbi.nlm.nih.gov/pubmed/32954302
http://dx.doi.org/10.1093/braincomms/fcaa050
_version_ 1783570485795094528
author Oishi, Tatsuya
Kogelschatz, Cory J
Young, Nathan P
Hoffmann, Ernest M
Staff, Nathan P
Visscher, Sue L
Borah, Bijan J
Krauss, William E
Arumaithurai, Kogulavadanan
Shelly, Shahar
Ansell, Stephen M
Klein, Christopher J
author_facet Oishi, Tatsuya
Kogelschatz, Cory J
Young, Nathan P
Hoffmann, Ernest M
Staff, Nathan P
Visscher, Sue L
Borah, Bijan J
Krauss, William E
Arumaithurai, Kogulavadanan
Shelly, Shahar
Ansell, Stephen M
Klein, Christopher J
author_sort Oishi, Tatsuya
collection PubMed
description Our study aims to quantitate neuromuscular morbidity from radiotherapy in Hodgkin lymphoma including: (i) frequency and (ii) time of onsets for neurological localizations; (iii) degree of disabilities and (iv) number of clinical visits compared to cardiopulmonary Hodgkin lymphoma-radiation complications. Medical records from Mayo Health systems were retrieved; identifying neuromuscular radiation treated Hodgkin lymphoma-complications from 1 January 1994 to 31 December 2016. Of an estimated 4100 post-radiotherapy Hodgkin lymphoma patients, 4.6% (189) were identified with complications. Mean latency to physician visit for symptoms was 23.7 years (range: 1–50). Most commonly identified complications included: head drop 10% (19) with or without myopathy, myopathy 39% (73), plexopathy 29% (54), myelopathy 27% (51) and polyradiculopathy 13% (24). Other findings included benign and malignant nerve sheath tumours 5% (9), phrenic and long thoracic mononeuropathies 7% (14) and compressive spinal meningioma 2% (4). Patients frequently had multiple coexisting complications (single = 76% [144], double = 17% [33], triple = 4% [8], quadruple = 2% [4]). Cardiac 28% (53) and pulmonary 15% (29) complications were also seen in these patients. History of Hodgkin lymphoma was initially overlooked by neurologists (14.3%, 48/336 clinical notes). Hospital and outpatient visits for complications were frequent: neuromuscular 19% (77/411) versus cardiopulmonary 30% (125/411). Testing was largely exclusionary, except when imaging identified secondary malignancy. Modified Rankin score at diagnosis varied: 0–1 (55.8%), 2–3 (5.8%) and 4–5 (38.3%). Neuromuscular complications among post-radiation Hodgkin lymphoma are diverse, occurring in ∼1 of 20 having markedly delayed onsets often eluding diagnosis. Frequent care visits and major morbidity are common. Survivorship recommendations should recognize the diverse neurological complications.
format Online
Article
Text
id pubmed-7425393
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-74253932020-09-17 Expanded neuromuscular morbidity in Hodgkin lymphoma after radiotherapy Oishi, Tatsuya Kogelschatz, Cory J Young, Nathan P Hoffmann, Ernest M Staff, Nathan P Visscher, Sue L Borah, Bijan J Krauss, William E Arumaithurai, Kogulavadanan Shelly, Shahar Ansell, Stephen M Klein, Christopher J Brain Commun Original Article Our study aims to quantitate neuromuscular morbidity from radiotherapy in Hodgkin lymphoma including: (i) frequency and (ii) time of onsets for neurological localizations; (iii) degree of disabilities and (iv) number of clinical visits compared to cardiopulmonary Hodgkin lymphoma-radiation complications. Medical records from Mayo Health systems were retrieved; identifying neuromuscular radiation treated Hodgkin lymphoma-complications from 1 January 1994 to 31 December 2016. Of an estimated 4100 post-radiotherapy Hodgkin lymphoma patients, 4.6% (189) were identified with complications. Mean latency to physician visit for symptoms was 23.7 years (range: 1–50). Most commonly identified complications included: head drop 10% (19) with or without myopathy, myopathy 39% (73), plexopathy 29% (54), myelopathy 27% (51) and polyradiculopathy 13% (24). Other findings included benign and malignant nerve sheath tumours 5% (9), phrenic and long thoracic mononeuropathies 7% (14) and compressive spinal meningioma 2% (4). Patients frequently had multiple coexisting complications (single = 76% [144], double = 17% [33], triple = 4% [8], quadruple = 2% [4]). Cardiac 28% (53) and pulmonary 15% (29) complications were also seen in these patients. History of Hodgkin lymphoma was initially overlooked by neurologists (14.3%, 48/336 clinical notes). Hospital and outpatient visits for complications were frequent: neuromuscular 19% (77/411) versus cardiopulmonary 30% (125/411). Testing was largely exclusionary, except when imaging identified secondary malignancy. Modified Rankin score at diagnosis varied: 0–1 (55.8%), 2–3 (5.8%) and 4–5 (38.3%). Neuromuscular complications among post-radiation Hodgkin lymphoma are diverse, occurring in ∼1 of 20 having markedly delayed onsets often eluding diagnosis. Frequent care visits and major morbidity are common. Survivorship recommendations should recognize the diverse neurological complications. Oxford University Press 2020-04-25 /pmc/articles/PMC7425393/ /pubmed/32954302 http://dx.doi.org/10.1093/braincomms/fcaa050 Text en © The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Article
Oishi, Tatsuya
Kogelschatz, Cory J
Young, Nathan P
Hoffmann, Ernest M
Staff, Nathan P
Visscher, Sue L
Borah, Bijan J
Krauss, William E
Arumaithurai, Kogulavadanan
Shelly, Shahar
Ansell, Stephen M
Klein, Christopher J
Expanded neuromuscular morbidity in Hodgkin lymphoma after radiotherapy
title Expanded neuromuscular morbidity in Hodgkin lymphoma after radiotherapy
title_full Expanded neuromuscular morbidity in Hodgkin lymphoma after radiotherapy
title_fullStr Expanded neuromuscular morbidity in Hodgkin lymphoma after radiotherapy
title_full_unstemmed Expanded neuromuscular morbidity in Hodgkin lymphoma after radiotherapy
title_short Expanded neuromuscular morbidity in Hodgkin lymphoma after radiotherapy
title_sort expanded neuromuscular morbidity in hodgkin lymphoma after radiotherapy
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425393/
https://www.ncbi.nlm.nih.gov/pubmed/32954302
http://dx.doi.org/10.1093/braincomms/fcaa050
work_keys_str_mv AT oishitatsuya expandedneuromuscularmorbidityinhodgkinlymphomaafterradiotherapy
AT kogelschatzcoryj expandedneuromuscularmorbidityinhodgkinlymphomaafterradiotherapy
AT youngnathanp expandedneuromuscularmorbidityinhodgkinlymphomaafterradiotherapy
AT hoffmannernestm expandedneuromuscularmorbidityinhodgkinlymphomaafterradiotherapy
AT staffnathanp expandedneuromuscularmorbidityinhodgkinlymphomaafterradiotherapy
AT visschersuel expandedneuromuscularmorbidityinhodgkinlymphomaafterradiotherapy
AT borahbijanj expandedneuromuscularmorbidityinhodgkinlymphomaafterradiotherapy
AT krausswilliame expandedneuromuscularmorbidityinhodgkinlymphomaafterradiotherapy
AT arumaithuraikogulavadanan expandedneuromuscularmorbidityinhodgkinlymphomaafterradiotherapy
AT shellyshahar expandedneuromuscularmorbidityinhodgkinlymphomaafterradiotherapy
AT ansellstephenm expandedneuromuscularmorbidityinhodgkinlymphomaafterradiotherapy
AT kleinchristopherj expandedneuromuscularmorbidityinhodgkinlymphomaafterradiotherapy